Immunotherapy for pancreatic cancer: A long and hopeful journey

被引：40

作者：

Xu, Jian-wei ^{[1
]}

Wang, Lei ^{[1
]}

Cheng, Yu-gang ^{[1
]}

Zhang, Guang-yong ^{[1
]}

Hu, San-yuan ^{[1
]}

Zhou, Bin ^{[2
]}

Zhan, Han-xiang ^{[1
]}

机构：

[1] Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan 250012, Shandong, Peoples R China

[2] Qingdao Univ, Affiliated Hosp, Dept Hepatopancreatobiliary Surg, Qingdao 266003, Shandong, Peoples R China

来源：

CANCER LETTERS | 2018年 / 425卷

关键词：

Pancreatic cancer; Immunotherapy; Tumor microenvironment; Vaccines; Monoclonal antibodies; T-CELL-ENGAGER; ALGENPANTUCEL-L IMMUNOTHERAPY; TUMOR-ASSOCIATED MACROPHAGES; STANDARD ADJUVANT THERAPY; PHASE-II TRIAL; MONOCLONAL-ANTIBODY; DOSE-ESCALATION; DENDRITIC CELLS; IMMUNE-SYSTEM; OPEN-LABEL;

D O I：

10.1016/j.canlet.2018.03.040

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple therapeutic strategies have been developed to treat pancreatic cancer, However, the outcomes of these approaches are disappointing. Due to deeper understandings of the pivotal roles of the immune system in pancreatic cancer tumorigenesis and progression, novel therapeutic strategies based on immune cells and the tumor microenvironment are being investigated. Some of these approaches, such as checkpoint inhibitors, chimeric antigen receptor T-cell therapy, and BiTE antibodies, have achieved exciting outcomes in preclinical and clinical trials. The current review describes the roles of immune cells and the immunosuppressive microenvironment in the development of pancreatic cancer, as well as the preclinical and clinical outcomes and benefits of recent immunotherapeutic approaches, which may help us further disclose the mechanisms of pancreatic cancer progression and the dialectical views of feasibility and effectiveness of immunotherapy in treatment of pancreatic cancer. (C) 2018 Elsevier B.V. All rights reserved.

引用

页码：143 / 151

页数：9

共 101 条

[51] Current perspectives in immunotherapy [J].

Lillehei, KO ;

Liu, Y ;

Kong, QZ .

ANNALS OF THORACIC SURGERY, 1999, 68 (03) :S28-S33

[52] A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation [J].

Lutz, Eric ;

Yeo, Charles J. ;

Lillemoe, Keith D. ;

Biedrzycki, Barbara ;

Kobrin, Barry ;

Herman, Joseph ;

Sugar, Elizabeth ;

Piantadosi, Steven ;

Cameron, John L. ;

Solt, Sara ;

Onners, Beth ;

Tartakovsky, Irena ;

Choi, Miri ;

Sharma, Rajni ;

Illei, Peter B. ;

Hruban, Ralph H. ;

Abrams, Ross A. ;

Le, Dung ;

Jaffee, Elizabeth ;

Laheru, Dan .

ANNALS OF SURGERY, 2011, 253 (02) :328-335

[53] Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy [J].

Ma, Weijie ;

Gilligan, Barbara M. ;

Yuan, Jianda ;

Li, Tianhong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9

[54] Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study [J].

Martinelli, Giovanni ;

Boissel, Nicolas ;

Chevallier, Patrice ;

Ottmann, Oliver ;

Goekbuget, Nicola ;

Topp, Max S. ;

Fielding, Adele K. ;

Rambaldi, Alessandro ;

Ritchie, Ellen K. ;

Papayannidis, Cristina ;

Sterling, Lulu Ren ;

Benjamin, Jonathan ;

Stein, Anthony .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) :1795-+

[55] Vaccination with poly (IC: LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer [J].

Mehrotra, Shikhar ;

Britten, Carolyn D. ;

Chin, Steve ;

Garrett-Mayer, Elizabeth ;

Cloud, Colleen A. ;

Li, Mingli ;

Scurti, Gina ;

Salem, Mohamed L. ;

Nelson, Michelle H. ;

Thomas, Melanie B. ;

Paulos, Chrystal M. ;

Salazar, Andres M. ;

Nishimura, Michael I. ;

Rubinstein, Mark P. ;

Li, Zihai ;

Cole, David J. .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10

[56] Cancer immunotherapy comes of age [J].

Mellman, Ira ;

Coukos, George ;

Dranoff, Glenn .

NATURE, 2011, 480 (7378) :480-489

[57] Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial [J].

Middleton, Gary ;

Silcocks, Paul ;

Cox, Trevor ;

Valle, Juan ;

Wadsley, Jonathan ;

Propper, David ;

Coxon, Fareeda ;

Ross, Paul ;

Madhusudan, Srinivasan ;

Roques, Tom ;

Cunningham, David ;

Falk, Stephen ;

Wadd, Nick ;

Harrison, Mark ;

Corrie, Pippa ;

Iveson, Tim ;

Robinson, Angus ;

McAdam, Karen ;

Eatock, Martin ;

Evans, Jeff ;

Archer, Caroline ;

Hickish, Tamas ;

Garcia-Alonso, Angel ;

Nicolson, Marianne ;

Steward, William ;

Anthoney, Alan ;

Greenhalf, William ;

Shaw, Victoria ;

Costello, Eithne ;

Naisbitt, Dean ;

Rawcliffe, Charlotte ;

Nanson, Gemma ;

Neoptolemos, John .

LANCET ONCOLOGY, 2014, 15 (08) :829-840

[58] Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients [J].

Miyazawa, Motoki ;

Katsuda, Masahiro ;

Maguchi, Hiroyuki ;

Katanuma, Akio ;

Ishii, Hiroshi ;

Ozaka, Masato ;

Yamao, Kenji ;

Imaoka, Hiroshi ;

Kawai, Manabu ;

Hirono, Seiko ;

Okada, Ken-ichi ;

Yamaue, Hiroki .

INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (04) :973-982

[59] Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial [J].

Mulvihlll, S ;

Warren, R ;

Venook, A ;

Adler, A ;

Randlev, B ;

Heise, C ;

Kirn, D .

GENE THERAPY, 2001, 8 (04) :308-315

[60] Stromal biology and therapy in pancreatic cancer: a changing paradigm [J].

Neesse, Albrecht ;

Alguel, Hana ;

Tuveson, David A. ;

Gress, Thomas M. .

GUT, 2015, 64 (09) :1476-1484

← 1 2 3 4 5 6 7 8 9 10 →